FORMULATION, DEVELOPMENT AND EVALUATION OF EXTENDED RELEASE MATRIX TABLETS OF GLIPIZIDE

Glipizide is used for treatment of type 2 diabetes mellitus. It is IInd generation sulfonylurea derivative. It is BCS class 2 drug and has a half life of 2-4 hours. The usual dosage is 2.5, 5 and 10 mg twice or thrice a day. To reduce the frequency of administration and to improve the patient compliance, a once daily extended release formulation of Glipizide is desirable. Hence selection of rate controlling excipient is necessary to achieve a constant in vivo input of drug. Hence in the present work an attempt has been made to develop extended release matrix tablets of Glipizide using hydrophilic matrix materials such as hydroxy propyl methyl cellulose and Ethyl cellulose. The most commonly used method of modulating the drug release is to include it in a matrix system. Diffusion controlled polymeric matrix systems have been widely used as drug delivery systems owing to their flexibility to obtain a desirable drug release profile, cost effectiveness and broad regulatory acceptance.